公开(公告)号：US20070190180A1

公开(公告)日：2007-08-16

申请号：US11592714

申请日：2006-11-03

申请人： Frank Pilkiewicz ,  Roman Perez-Soler ,  Walter Perkins ,  Yiyu Zou ,  Mary Neville ,  Jin Lee

发明人： Frank Pilkiewicz ,  Roman Perez-Soler ,  Walter Perkins ,  Yiyu Zou ,  Mary Neville ,  Jin Lee

IPC分类号： A61K33/24 ,  A61K31/555 ,  A61K31/282

CPC分类号： A61K31/555 ,  A61K9/0019 ,  A61K9/127 ,  A61K31/282 ,  A61K33/24

摘要： In one aspect, the present invention relates to methods of treating cancer in a patient comprising administering intravenously to a patient in need thereof a cancer treating effective amount of a lipid-based platinum compound formulation wherein the concentration of the platinum compound of the lipid-based platinum compound formulation is greater than about 1.2 mg/ml.

摘要翻译： 一方面，本发明涉及在患者中治疗癌症的方法，包括向有需要的患者静脉内施用治疗有效量的基于脂质的铂化合物制剂的癌症，其中所述脂质基铂化合物的铂化合物的浓度 铂化合物制剂大于约1.2mg / ml。

公开(公告)号：US20070190181A1

公开(公告)日：2007-08-16

申请号：US11592729

申请日：2006-11-03

申请人： Frank Pilkiewicz ,  Roman Perez-Soler ,  Yiyu Zou ,  Mary Neville

发明人： Frank Pilkiewicz ,  Roman Perez-Soler ,  Yiyu Zou ,  Mary Neville

IPC分类号： A61K33/24 ,  A61K31/555 ,  A61K31/282

CPC分类号： A61K31/555 ,  A61K9/0019 ,  A61K9/127 ,  A61K31/282 ,  A61K33/24

摘要： In one aspect, the present invention relates to methods of treating cancer in a patient comprising administering intravenously to a patient in need thereof a cancer treating effective amount of a lipid-based platinum compound formulation.

摘要翻译： 一方面，本发明涉及在患者中治疗癌症的方法，包括向有需要的患者静脉内施用治疗有效量的基于脂质的铂化合物制剂的癌症。

公开(公告)号：US5658744A

公开(公告)日：1997-08-19

申请号：US277299

申请日：1994-07-22

申请人： Augusto C. Ochoa ,  Howard A. Young ,  Dan L. Longo ,  Paritosh Ghosh ,  Richard Robb ,  Mary Neville

发明人： Augusto C. Ochoa ,  Howard A. Young ,  Dan L. Longo ,  Paritosh Ghosh ,  Richard Robb ,  Mary Neville

IPC分类号： G01N33/53 ,  C12Q1/02 ,  C12Q1/24 ,  C12Q1/68 ,  G01N33/50 ,  G01N33/564 ,  G01N33/569 ,  G01N33/68

CPC分类号： G01N33/68 ,  G01N33/5091 ,  G06F19/3431

摘要： Methods of identifying a patient having an altered immune status involve determining an immune status index for the patient and comparing it to the immune status index in healthy individuals. In general, an immune status index is the ratio of the amount of a protein that varies significantly in a patient with an altered immune status to the amount of another protein that is substantially invariant in both healthy and immune-altered individuals. Variable proteins can be TCR subunit proteins, T lymphocyte signal transduction pathway proteins, polynucleotide binding proteins or biological response modifiers (BRM). In addition, the ratio of a TH-1-type BRM to a TH-2-type BRM, the ratio of cytoplasmic to nuclear levels of polynucleotide binding proteins, the pattern of protein binding to an oligonucleotide probe that comprises the protein binding region of a gene for a BRM, or the pattern of distribution of T lymphocytes in a density gradient following density gradient centrifugation are also suitable as an immune status index. The methods are useful in identifying patients exhibiting immunosuppression, hyperimmunity and autoimmunity, as well as in assessing the immune status of a patient undergoing organ transplant.

摘要翻译： 识别具有改变的免疫状态的患者的方法包括确定患者的免疫状态指数并将其与健康个体的免疫状态指数进行比较。 通常，免疫状态指数是在具有改变的免疫状态的患者中显着变化的蛋白质的量与健康和免疫改变个体中基本上不变的另一蛋白质的量的比率。 可变蛋白可以是TCR亚基蛋白，T淋巴细胞信号转导通路蛋白，多核苷酸结合蛋白或生物反应调节剂（BRM）。 此外，TH-1型BRM与TH-2型BRM的比例，多核苷酸结合蛋白质的细胞质与核水平的比例，蛋白质与寡核苷酸探针结合的模式，其包含蛋白质结合区域 用于BRM的基因或密度梯度离心后的密度梯度中T淋巴细胞的分布模式也适合作为免疫状态指数。 该方法可用于鉴定表现出免疫抑制，超免疫和自身免疫的患者以及评估接受器官移植的患者的免疫状态。